<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05048173</url>
  </required_header>
  <id_info>
    <org_study_id>110187-E</org_study_id>
    <nct_id>NCT05048173</nct_id>
  </id_info>
  <brief_title>Sentinel Lymph Node Biopsy Versus Lymphadenectomy in Endometrial Cancer</brief_title>
  <official_title>Sentinel Lymph Node Biopsy Versus Pelvic Lymphadenectomy in Early Stage Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Far Eastern Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Far Eastern Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare sentinel lymph nodes biopsy versus comprehensive lymphadenectomy in patients with&#xD;
      early stage endometrial cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This retrospective study aims to compare sentinel lymph nodes biopsy versus comprehensive&#xD;
      lymphadenectomy in patients with early stage endometrial cancer by reviewing the medical&#xD;
      records.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 20, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>4 years</time_frame>
    <description>The length of time from the day of operation till recurrence or last follow up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>4 years</time_frame>
    <description>The length of time from the day of operation till death (of any cause) or last follow up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>surgical complications related to lymph node biopsy or lymphadenectomy</measure>
    <time_frame>from the day of operation till post-operative 6 months</time_frame>
    <description>asymptomatic lymphocele, lymphedema, infected lymphocele</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Early Stage Endometrial Cancer</condition>
  <condition>Sentinel Lymph Nodes</condition>
  <condition>Lymphadenectomy</condition>
  <arm_group>
    <arm_group_label>Sentinel lymph node group</arm_group_label>
    <description>woman who had sentinel lymph node mapping and biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lymphadenectomy group</arm_group_label>
    <description>woman who underwent traditional pelvic lymphadenectomy without sentinel lymph node mapping</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sentinel lymph node mapping and biopsy</intervention_name>
    <description>Sentinel lymph node mapping with indocyanine green dye followed by biopsy if positive</description>
    <arm_group_label>Sentinel lymph node group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lymphadenectomy</intervention_name>
    <description>Conventional lymphadenectomy</description>
    <arm_group_label>Lymphadenectomy group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women aged 20 and above, diagnosed with early stage endometrial cancer (FIGO stage I), who&#xD;
        had received staging surgery between 01 July 2017 and 19 August 2021 were included in the&#xD;
        study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  â‰§ 20 years&#xD;
&#xD;
          -  early stage endometrial cancer (FIGO stage I)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Did not receive a complete course of treatment in this hospital, interrupted the&#xD;
             treatment halfway (except if the disease continued to deteriorate or caused death&#xD;
             during treatment), and did not follow up in this hospital after the course of&#xD;
             treatment.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>early stage endometrial cancer</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sheng-Mou Hsiao, MD</last_name>
    <phone>+886919302632</phone>
    <email>smhsiao2@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital</name>
      <address>
        <city>Banqiao</city>
        <state>New Taipei</state>
        <zip>22050</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Sheng-Mou Hsiao, M.D.</last_name>
      <phone>+886-2-89667000</phone>
      <phone_ext>1818</phone_ext>
      <email>smhsiao2@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 18, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Far Eastern Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Sheng-Mou Hsiao</investigator_full_name>
    <investigator_title>Chief of Department of Obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

